These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31019437)

  • 1. What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?
    Busse A; Lüftner D
    Breast Care (Basel); 2019 Mar; 14(1):10-16. PubMed ID: 31019437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
    Moorkens E; Vulto AG; Huys I
    MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
    Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
    Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database.
    Nikitina V; Santi Laurini G; Montanaro N; Motola D
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The development of biosimilars in oncology].
    Jiang SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
    Barbier L; Simoens S; Soontjens C; Claus B; Vulto AG; Huys I
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS; Coiffier B; Kwon HC; Kim S
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database.
    Xue X; Qian J
    Expert Opin Drug Saf; 2024 May; ():1-10. PubMed ID: 38680112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States.
    Xue X; Truong B; Qian J
    Expert Opin Biol Ther; 2023; 23(8):841-849. PubMed ID: 36892184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies.
    Safdar A; Butt MH; Ahmad A; Zaman M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1195-1204. PubMed ID: 34096401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinician's guide to biosimilars in oncology.
    Rugo HS; Linton KM; Cervi P; Rosenberg JA; Jacobs I
    Cancer Treat Rev; 2016 May; 46():73-9. PubMed ID: 27135548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody biosimilars for cancer treatment.
    Broer LN; Knapen DG; de Groot DA; Mol PGM; Kosterink JGW; de Vries EGE; Lub-de Hooge MN
    iScience; 2024 Jun; 27(6):110115. PubMed ID: 38974466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.
    Vandenplas Y; Simoens S; Van Wilder P; Vulto AG; Huys I
    Front Pharmacol; 2021; 12():644187. PubMed ID: 33953678
    [No Abstract]   [Full Text] [Related]  

  • 18. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars.
    Barbier L; Declerck P; Simoens S; Neven P; Vulto AG; Huys I
    Br J Cancer; 2019 Jul; 121(3):199-210. PubMed ID: 31257362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: Implications for Clinical Practice.
    Rifkin RM; Peck SR
    J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.